Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
about
The Rationale for Insulin Therapy in Alzheimer's DiseaseDiverse molecular targets for therapeutic strategies in Alzheimer's diseaseElevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brainDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseMetformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathyThe anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complexGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideRole of anti-diabetic drugs as therapeutic agents in Alzheimer's diseaseApplication of artificial neural networks to investigate one-carbon metabolism in Alzheimer's disease and healthy matched individualsMetformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.Antioxidant and Anti-Senescence Effect of Metformin on Mouse Olfactory Ensheathing Cells (mOECs) May Be Associated with Increased Brain-Derived Neurotrophic Factor Levels-An Ex Vivo Study.Berberine Ameliorates Diabetes-Associated Cognitive Decline through Modulation of Aberrant Inflammation Response and Insulin Signaling Pathway in DM Rats.Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice.Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases.Metformin in the diabetic brain: friend or foe?Insulin resistance in Alzheimer's disease.Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changesModulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's DiseaseDemonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance.Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study.Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway.Metformin: an old but still the best treatment for type 2 diabetes.Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies.Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study.Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism.Roles of AMP-activated protein kinase in Alzheimer's disease.Overlapped metabolic and therapeutic links between Alzheimer and diabetes.A review: treatment of Alzheimer's disease discovered in repurposed agents.Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study.Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.Metformin Accelerates Glycolytic Lactate Production in Cultured Primary Cerebellar Granule Neurons.Glycation in Parkinson's disease and Alzheimer's disease.
P2860
Q26744834-A72E980C-C1FD-4D78-AA85-E5DDB34E4F56Q26827193-75D19C6C-407F-4236-938C-A9EDF00DC5DDQ27003253-A23BF88F-C18F-494C-8DDE-AA2C64908119Q27024122-A5EC4BD2-406E-4D17-B3FA-2EB3288EA977Q27301246-7FBC40C7-6FE4-4682-B1B1-D1FA9407FCB2Q27319458-C83BA82A-2642-4C08-96BB-7174D4D47788Q28081671-710750CC-7AF4-4F06-AA0B-16FB0CBAF5DDQ28083039-70F22A79-C0DD-467D-A146-7CED4439565EQ28535239-55969496-1FD4-4B9F-AEAA-8C8D9049DC6DQ30419141-E11F6509-D01E-4899-82AB-1B8A58B53C68Q33624944-C7608630-8850-422D-A7CB-40DF298C0230Q33766908-34E7FA71-2091-4379-A70E-1848414151D1Q33789329-ED5EF36E-6A98-4533-BACB-D87BE53B11F4Q33800802-6EDCBCB3-88A5-4187-9173-7E7B1F460F02Q33850466-48E2E3B7-A79E-4CA1-9547-94429ACA40A9Q34012029-4941C406-981D-46C1-8EE2-E963475FA40CQ34357977-29D10825-28CE-4EB8-B7F9-17BAEACE89DCQ34622157-E4035BD3-A1F2-402A-B8CC-0C0FF364FAB2Q35070855-6E5508C0-ACC2-4C4B-980B-9402E87745CFQ35733751-F06E0EF5-1B07-4784-A0AC-A1F65A9EAA18Q35858095-BB07CF41-67C8-49E5-816A-2F4FFB41AB7EQ36284520-704B15CE-6B90-4145-A0D0-D152F86EF900Q36379186-D3526532-94B4-4FCD-A8D8-341D45B20C1AQ36410706-2999E87F-150D-41DA-807E-BF2295596F04Q36715464-2DB75DED-D4C3-4461-820F-FBDA7ACAB761Q37158071-E3422F2A-1D66-4B7B-B42D-D920EC2F321AQ37164474-3E0BF590-2120-416F-9150-DEFBAD2500A6Q37364862-805E0A54-1B21-434A-8EDA-EDAAC1F72C95Q37529582-6642D74C-1BE9-40C4-B030-15B648DAFD17Q37924942-AF993754-D670-493B-88AD-7C1ED91F6075Q37988399-C15EBF50-8FBD-4E18-BFC7-97EB8807C4C5Q38046539-93868B30-6D6E-4FF0-ABD7-DB1905DBC236Q38073138-130872C3-A894-443F-971E-B9E8148AC22AQ38091301-7DC23CFD-7335-452D-9DE0-F8D2EED6448EQ38234927-A208059B-A6B0-44B2-BBA7-678C9EFFBE5AQ38396373-955F5BAB-BA5F-4943-B95F-01E597F6D33DQ38433563-31D475C1-0CAB-4ABB-A2D4-A51A85B8DD83Q38673914-DE8ADB4A-425F-458A-9B4E-4FF878EE1299Q38688703-A37AA244-92AD-417D-966C-0D68DED6783AQ38762228-357F91D2-5D0A-40DE-BBF4-82276BBFC4C0
P2860
Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@en
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@nl
type
label
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@en
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@nl
prefLabel
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@en
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@nl
P2093
P921
P1433
P1476
Peripheral insulin-sensitizer ...... and Alzheimer's-like changes.
@en
P2093
Amit Gupta
Bharti Bisht
Chinmoy Sankar Dey
P304
P356
10.1016/J.NEUROPHARM.2011.01.033
P577
2011-01-26T00:00:00Z